Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals Stock
Pacira Pharmaceuticals gained 0.860% compared to yesterday.
Our community is currently high on Pacira Pharmaceuticals with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 30 € shows a positive potential of 28.21% compared to the current price of 23.4 € for Pacira Pharmaceuticals.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | 0.860% | -1.724% | 2.703% | 21.925% | 5.556% | -34.483% | -54.400% |
| Supernus Pharmaceuticals | 14.510% | -3.500% | -7.656% | 26.974% | -10.233% | 33.103% | 70.796% |
| Corcept Therapeutics Inc. | -2.960% | 22.242% | 25.500% | 64.219% | 43.229% | 242.448% | 438.132% |
| Collegium Pharmaceutical Inc | 0.000% | -1.923% | -4.969% | 19.531% | -26.087% | 53.769% | 45.714% |
Comments
Pacira BioSciences (PCRX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (PCRX) had its price target raised by Needham & Company LLC from $30.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences (NASDAQ:PCRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat